You are here: Home » Current Affairs » News » Human Interest
Business Standard

Glenmark launches fixed-dose combination medication for diabetic patients

Glenmark Pharmaceuticals on Monday said it has launched a novel fixed-dose combination (FDC) of Teneligliptin, with Pioglitazone in India for adults.

Diabetes drug | diabetes treatment | Glenmark Pharmaceuticals

Press Trust of India  |  New Delhi 

Glenmark Pharmaceuticals
Glenmark Pharmaceuticals

on Monday said it has launched a novel fixed-dose combination (FDC) of Teneligliptin, with Pioglitazone in India for adults with uncontrolled Type 2 diabetes.

Glenmark has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) and Pioglitazone (15 mg), to be taken once a day, the company said in a statement.

Diabetes is a key area of focus for Glenmark; a pioneer in providing access to the latest treatment options to diabetic patients in India. We are delighted to introduce this novel Zita Plus Pio, which is the first of its kind in India; offering a world-class and affordable treatment option to adult diabetic patients, Group Vice President & Head, India Formulations Alok Malik said.

Glenmark claimed it is the "first company in India to market the innovative FDC of Teneligliptin + Pioglitazone, which is approved by the DCGI (Drug Controller General of India)"

"This fixed-dose combination will be useful for patients who require treatment with Teneliglitptin and Pioglitazone (as separate drugs) to improve glycemic control reducing insulin resistance," the company said.

In Type 2 diabetes, there is an impairment in the regulation of sugar by the body, mainly due to cells responding poorly to insulin, thereby resulting in high level of sugar circulating in the bloodstream.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, April 25 2022. 13:03 IST